Ulrich Meier,Nicole Bieri,Dieter Becker,Julien Taillemite,Marie-Pierre Filliot,Tanja Meister
申请号：
US13990632
公开号：
US08987285B2
申请日:
2011.12.05
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.
